Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.53 |
| ▸ | CNR2 | P34972 | 5/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | BCL3 | P20749 | 1/20 | 0.47 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046921 | 0.89 | CCR8 (0.51) | CNR1CNR2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13046914 | 0.89 | HTT (0.52) | CNR1CNR2KDM4EHTTPOLB | |
| SCHEMBL13046922 | 0.86 | SMN1; SMN2 (0.46) | CNR1CNR2KDM4EALDH1A1MAPT | |
| SCHEMBL13047425 | 0.85 | CYP1A2 (0.56) | CNR2KDM4EHTTGAAMAPT | |
| SCHEMBL13046947 | 0.85 | KDM4E (0.55) | CNR1CNR2KDM4EHTTGAA | |
| SCHEMBL13047039 | 0.85 | SMN1; SMN2 (0.45) | CNR1CNR2KDM4EHTTPOLB | |
| SCHEMBL13046982 | 0.85 | CNR2 (0.45) | CNR1CNR2KDM4EHTTGAA | |
| SCHEMBL13046993 | 0.85 | RXFP1 (0.45) | CNR1CNR2HTTPOLBBCL3 | |
| SCHEMBL13046967 | 0.84 | NPC1 (0.56) | CNR2KDM4EHTTPOLBALDH1A1 | |
| SCHEMBL13046753 | 0.83 | CNR1 (0.55) | CNR1CNR2BACE1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | CNR1 49/4885CNR2 42/4885BACE1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.